← Back to Search

Corticosteroid

Hydrocortisone for Memory Impairment

Phase 4
Recruiting
Led By Sherwood Brown, MD, PhD
Research Sponsored by University of Texas Southwestern Medical Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Baseline QIDS-C between 11-20 (≥ moderate depressive symptoms but < very severe depressive symptoms) for the 'depressed' group
BMI between 18.5-35.0 (neither underweight nor severely obese)
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 3 days
Awards & highlights

Study Summary

This trial will use hydrocortisone or placebo to study the effects of chronic corticosteroid exposure on memory and the hippocampus in both men and women.

Who is the study for?
This trial is for men and women aged 18-40 with normal to slightly overweight BMI, at least a high school education, and normal memory function. Healthy participants must have minimal depressive symptoms, while the depressed group should have moderate but not severe depression. Participants need good vision (correctable) for MRI tasks.Check my eligibility
What is being tested?
The study tests how a short-term high-dose hydrocortisone treatment affects memory and brain structure/function in healthy individuals versus those with depression. It involves taking either hydrocortisone or a placebo pill and undergoing advanced neuroimaging to observe changes in specific areas of the hippocampus.See study design
What are the potential side effects?
Potential side effects from hydrocortisone may include mood swings, increased blood pressure, sleep problems, weight gain around the midsection or face (moon face), increased blood sugar levels, weakened bones over time if used long term.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
My depression is moderate to severe, but not very severe.
Select...
My BMI is between 18.5 and 35.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~3 days
This trial's timeline: 3 weeks for screening, Varies for treatment, and 3 days for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Hippocampal subfield activation
Hippocampal subfield volume

Trial Design

4Treatment groups
Experimental Treatment
Group I: Healthy Controls: Placebo, then HydrocortisoneExperimental Treatment2 Interventions
Participants in the "healthy control" arm will receive a Placebo tablet (matching Hydrocortisone 160 mg tablet) every day for 3 days. After a washout period of 25 days, they then will receive a Hydrocortisone 160 mg tablet every day for 3 days.
Group II: Healthy Controls: Hydrocortisone, then PlaceboExperimental Treatment2 Interventions
Participants in the "healthy control" arm will receive a Hydrocortisone 160 mg tablet every day for 3 days. After a washout period of 25 days, they then will receive a Placebo tablet (matching Hydrocortisone 160 mg tablet) every day for 3 days.
Group III: Depressed: Placebo, then HydrocortisoneExperimental Treatment2 Interventions
Participants in the "depressed' arm will receive a Placebo tablet (matching Hydrocortisone 160 mg tablet) every day for 3 days. After a washout period of 25 days, they then will receive a Hydrocortisone 160 mg tablet every day for 3 days.
Group IV: Depressed: Hydrocortisone, then PlaceboExperimental Treatment2 Interventions
Participants in the "depressed' arm will receive a Hydrocortisone 160 mg tablet every day for 3 days. After a washout period of 25 days, they then will receive a Placebo tablet (matching Hydrocortisone 160 mg tablet) every day for 3 days.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Placebo Oral Tablet
2017
Completed Phase 4
~2250

Find a Location

Who is running the clinical trial?

University of Texas Southwestern Medical CenterLead Sponsor
1,048 Previous Clinical Trials
1,053,547 Total Patients Enrolled
University of California, IrvineOTHER
544 Previous Clinical Trials
1,922,855 Total Patients Enrolled
1 Trials studying Hydrocortisone
158 Patients Enrolled for Hydrocortisone
National Institute of Mental Health (NIMH)NIH
2,786 Previous Clinical Trials
2,689,511 Total Patients Enrolled

Media Library

Hydrocortisone (Corticosteroid) Clinical Trial Eligibility Overview. Trial Name: NCT03896659 — Phase 4
Hydrocortisone Research Study Groups: Depressed: Placebo, then Hydrocortisone, Depressed: Hydrocortisone, then Placebo, Healthy Controls: Hydrocortisone, then Placebo, Healthy Controls: Placebo, then Hydrocortisone
Hydrocortisone Clinical Trial 2023: Hydrocortisone Highlights & Side Effects. Trial Name: NCT03896659 — Phase 4
Hydrocortisone (Corticosteroid) 2023 Treatment Timeline for Medical Study. Trial Name: NCT03896659 — Phase 4
Hydrocortisone Patient Testimony for trial: Trial Name: NCT03896659 — Phase 4

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What is the participant count for this trial?

"Confirmed. According to clinicaltrials.gov, the trail was initially published on October 1st 2019 and has been updated most recently on February 17th 2022. It is actively searching for 188 participants across one site."

Answered by AI

What other research has been undertaken in regards to Hydrocortisone Oral?

"Currently, 60 clinical trials are investigating the use of Hydrocortisone Oral with 20 in Phase 3. While New york City is home to a large portion of these studies, an expansive network of 3054 medical sites worldwide have some iteration of this investigation running."

Answered by AI

Has the US Food & Drug Administration granted clearance for Hydrocortisone Oral?

"As Hydrocortisone Oral has been approved by the authorities, its safety rating is 3 on a scale of 1-3."

Answered by AI

What ailments does Hydrocortisone Oral typically alleviate?

"Hydrocortisone Oral is primarily used to treat ulcerative colitis, but can also be employed for the management of various other ailments such as malignant neoplasms, varicella-zoster virus acute retinal necrosis and crohn disease."

Answered by AI

Are there any open enrollment opportunities for this clinical trial?

"Affirmative. The information accessible on clinicaltrials.gov confirms that this research study, initially posted in October of 2019 and recently updated on February 17th 2022 is currently recruiting patients. 188 individuals have to be recruited from a single location for the trial's completion."

Answered by AI

Are there any criteria that would bar someone from joining this research initiative?

"Eligible candidates for this medical trial must have hydrocortisone and be between 18 to 40 years old. A total of 188 participants will take part in the experiment."

Answered by AI

Is senior participation accepted in this experimental protocol?

"The parameters for this research endeavour require that all participants be at least 18 years of age and not surpass 40."

Answered by AI

Who else is applying?

What state do they live in?
Texas
What site did they apply to?
UT Southwestern Medical Center
What portion of applicants met pre-screening criteria?
Met criteria
Did not meet criteria
How many prior treatments have patients received?
0
3+

Why did patients apply to this trial?

I have had depression for a while and it effects my memory and I want a solution.
PatientReceived 1 prior treatment
I would like to be a help in finding drug that will help people and being a part of that study will be a privilege.
PatientReceived 2+ prior treatments

What questions have other patients asked about this trial?

How long does screening take?
PatientReceived no prior treatments

How responsive is this trial?

Average response time
  • < 2 Days
Typically responds via
Phone Call
Most responsive sites:
  1. UT Southwestern Medical Center: < 48 hours
~32 spots leftby Mar 2025